Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

@article{Guerrierigonzaga2016BenefitOL,
  title={Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.},
  author={Aliana Guerrieri-gonzaga and Ivana Sestak and Matteo Lazzeroni and Davide Serrano and Nicole Rotmensz and Massimiliano Cazzaniga and Clara Varricchio and Giancarlo Pruneri and Maria Cristina Leonardi and Roberto Orecchia and Viviana Enrica Galimberti and Bernardo Bonanni and Andrea U. Decensi},
  journal={International journal of cancer},
  year={2016},
  volume={139 9},
  pages={2127-34}
}
Low-dose tamoxifen has comparable antiproliferative effect to the standard dose of 20 mg/day in biomarker trials, but its clinical efficacy remains unclear. We assessed the effect of low-dose tamoxifen on ipsilateral recurrence in ductal carcinoma in situ (DCIS) patients treated in a referral Institution between 1996 and 2008. Following conserving surgery, women received radiotherapy and/or low-dose tamoxifen upon clinical judgment and patient preferences. Cox regression analyses were used with… CONTINUE READING